Mature human erythrocyte membranes contained specific, high affinity (Kd 3.3 X 10(-11) M) folate binding moieties. Folate binding was pH, time-and temperature-dependent, saturable, and was much greater for pteroylmonoglutamate and 5-methyltetrahydrofolate than 5-formyltetrahydrofolate and amethopterin. On detergent solubilization of membranes, two peaks of specific folate binding with Mr greater than or equal to 200,000 and 160,000 were identified on Sephacryl S-200 gel filtration chromatography in Triton X-100, and this corresponded to two similar peaks of immunoprecipitated material when solubilized iodinated membranes were probed with anti-human placental folate receptor antiserum. Age-dependent separation of erythrocytes by Stractan density gradients revealed a sevenfold greater folate binding capacity in membranes purified from younger compared with aged erythrocytes. Since this difference was not reflected in proportionately higher immunoreactive folate binding protein, (as determined by a specific radioimmunoassay for these proteins), or differences in affinity in younger than aged cells, these findings indicate that erythrocyte folate binding proteins become progressively nonfunctional at the onset of red cell aging. 
Introduction
The intracellular role offolates as donors ofone-carbon groups in enzyme reactions that lead to DNA synthesis has been well documented, and an adequate supply of folates must be assured each cell since folate deficiency leads to disordered DNA synthesis and consequent cell death (1) . Therefore, specific mechanisms for cellular folate uptake and its retention could exist physiologically. This is most convincingly suggested in the developing human fetus, which concentrates and assures itself adequate folate stores even in the presence of maternal folate deficiency (1, 2) . This suggests that a folate concentrating mechanism is mediated by the placenta, the organ that transfers nutrients between the maternal and fetal circulation. Based on these clinical observations, we identified, purified, and characterized a human placental particulate membraneassociated folate binding protein that had a high affinity for 5-methyltetrahydrofolate in the range for binding folates in serum (3) . Although the hypothesis that these placental folate binding proteins are involved in transplacental transport of folates in humans cannot be further tested in vivo, taken together, the clinical observations and experimental studies are supporting (albeit indirect) evidence that these proteins may act as physiologically relevant specific folate receptors in human placenta (4) . At the cellular level, it has long been speculated that other particulate folate binding proteins (PFBPs)l in a variety of human tissues (5-7) have some important role in folate metabolism, either as intracellular folate storage proteins or as carriers for the transmembrane transport of folates. However, only in a human nasopharyngeal carcinoma cell line in culture, has there been direct evidence for a specific transport role for such externally oriented high affinity P-FBPs in human cells (8) . To identify whether folate receptors are unique to malignant human cells, it is necessary to investigate their presence in other normal human cells that have been shown to transport folate intracellularly. Earlier, antiserum to purified placental folate receptors (PFR) identified moieties with shared antigenic determinants in mature human erythrocytes (3) . Since human erythrocytes can take up folates (9) (10) (11) and retain them intracellularly (1), these cells seemed a logical choice to investigate for the presence of PFBPs. Such studies have not been performed with these or other homogeneous plasma membranes from normal human cells. A novel stable folate analogue, (a histamine derivative of folic acid), with a specific activity 40-50-fold higher than any previously available radiolabeled folate, allowed for the identification ofproteins on erythrocyte membranes that have folate binding characteristics that are similar to that reported in human KB cells (12) . Solubilization of radioligand-bound as well as radioiodinated membranes released folate binding proteins and iodinated proteins, respectively, that were specifically immunoprecipitated by anti-PFR antiserum. Further quantitation of these solubilized moieties by a specific, sensitive radioimmunoassay (RIA) to the PFR and correlation with the particulate membrane ligand binding assay allowed for a study of the age-related changes of folate binding proteins in young and old erythrocytes.
Methods
A histamine derivative of folic acid, -carboxy-34N4244-imidazo1yl)ethyl)carbamoyl)-1-pteroylaminopropane, was synthesized by Dupont/New England Nuclear, Boston, MA, and iodinated by the method ofHunter and Greenwood (13) IL) . Pteroylglutamate (PteGlu, 99% pure), d,l-5-methyltetrahydrofolate (90% pure), amethopterin (90% pure) and 5-formyltetrahydrofolate (90% pure), Sephacryl S-200, blue dextran, phenylmethylsulfonyl fluoride (PMSF), 2-mercaptoethanol (2-ME) Triton X-100, dimethylsulfoxide, monobasic and dibasic sodium phosphate and potassium phosphate, sodium deoxycholate, NP-40, the test kit for measuring total hemoglobin, arabinogalactan (Stractan), Amberlite MB-4B, triethanolamine (TEA), phosphoenolpyruvate (PEP), NADH, lactic dehydrogenase (LDH), and adenine dinucleotide phosphate, (ADP), were obtained from Sigma Chemical Company, St. Louis, MO. Beef lung heparin was from Upjohn Co., Kalamazoo, MI. IgG Sorb, a 10% cell suspension of formalin-fixed Staphylococcus aureus cells bearing protein A was obtained from The Enzyme Center, Inc., Boston, MA. Iodogen (1,2,4,6-tetrachloro-3a,6a-diphenylglycouril) was obtained from Pierce Chemical Co., Rockford, IL. Determination of the purity and stability of '251-labeled PteGlu (histamine derivative). Since a novel radiolabeled folate compound was used, it was necessary to determine its purity and stability under various experimental conditions used to identify folate binding sites on erythrocyte membranes. Analysis for purity was determined by high performance liquid chromatography (HPLC) and thin-layer chromatography (TLC); both techniques have been recently used to establish the purity of and purify folates (8) . The HPLC apparatus (Waters Associates, Milford, MA) consisted of two model 510 pumps connected to a U6K injector (2 ml capacity), a (Lambda-Max model 481 LC) spectrophotometer (set at 0.005 AUFS) connected to a model 1200 linear recorder (set at 30 cm/h) and a 3.9 mm X 30 cm uBondapak C18 stainless steel column. The column was run isocratically in 84% buffer A (5 mM Pic A, 10 mM KH2PQ4: H3Po4, pH 5.5) and 16% buffer B (acetonitrile). The column flow rate was 1 ml/min and 0.5-ml fractions were collected and counted for radioactivity. Samples were routinely suspended in 250-iA column equilibration buffer before injection. Thin-layer chromatography analysis was performed by application of radiolabeled folate samples (5 gl) to Avicel microcrystalline cellulose plates (20 X 20 cm, 250 ,um, Analtech, Newark, DE) developed in N-propanol: NH40H 7:3 at room temperature. The plates were subsequently dried and subjected to autoradiography using Kodak X-omat AR film and Cronex Lighting Plus intensifying screens at -70°C. Samples subjected to HPLC and TLC analyses were as follows: (a) commercially supplied '251-labeled PteGlu (histamine derivative); (b) an aliquot ofthe peak fraction from sample a after HPLC; (c) sample b that was incubated for 2 h at 37°C. (d) To determine ifthe peak fraction from HPLC (which corresponded to maximal absorbance at A280 as well as the maximum radioactivity) was authentic '251-labeled PteGlu (histamine derivative), its specific binding to erythrocyte membranes was compared to an equivalent amount of unfractionated '251-labeled PteGlu (histamine derivative); the radioactivity that was eluted by low pH (5.5) washes after binding of unfractionated or HPLC purified '251-labeled PteGlu (histamine derivative) to erythrocyte membranes (see below), was also analyzed by TLC to determine if the eluted radioactivity corresponded to authentic '251-labeled PteGlu (histamine derivative).
Preparation ofpurified erythrocyte membranes. Erythrocyte membranes were prepared from whole blood collected in heparin (33 U/ml) obtained from normal human volunteers (whose reticulocyte count was not > 1%) and 99% of leukocytes were removed as previously described (3). After four centrifuge-wash cycles at 1,000 gfor 10 min at 4°C with 10 vol 0.01 M potassium phosphate (KPo4), pH 7.5 containing 0.15 M NaCl (phosphate-buffered saline, PBS) per wash cycle and aspiration ofthe supernatant with each wash, the pellets ofpacked cells were lysed by the method of Lieber and Steck (14) . The lysis buffer contained 5 . After incubation, the pellets were washed with the same pH buffer four times. After determination of the amount of membrane-bound radioligand at varying pH, the pellets were washed with 10 vol of lysis buffer (pH 8) for two cycles, (to uniformly neutralize the pH in membranes that were previously washed with various pH buffers), and mixed with 25 fmol '251-labeled PteGlu (histamine derivative) in 1 ml lysis buffer (pH 8). After incubation, the pellets were washed with lysis buffer (pH 8) and counted for bound radioactivity. All folate binding assays were routinely performed in triplicate and the data are expressed as a mean of three experiments. There was < 5% deviation of folate binding from the mean for each set ofassays. Erythrocyte membranes that were washed with lysis buffer pH 5.5 (to dissociate bound endogenous folate) were also assayed for the presence of endogeneous (bound) folate as previously described (8) . The upper limits of sensitivity of this assay was 50 fmol folate (range 50 fmol-5 pmol) using '251-labeled PteGlu (histamine derivative) as the radioligand. Membranes were prepared for this analysis as follows: 10 ml of membranes that were first washed with lysis buffer pH 5.5 as described above, were then resuspended in lysis buffer, pH 8, and sedimented in the ultracentrifuge (see below). After addition of 1 ml of "boiling" buffer (160 mM borate-KOH, pH 9.3, containing 150 mM NaCl and 2 MM dithiothreitol) and boiling at 100°C for 30 min, the membranes were sedimented again in the ultracentrifuge. The supernatant was subsequently analyzed for the presence of endogenous folate.
Molecular weight of erythrocyte folate binding proteins. Membranes purified from 20 ml of packed cells were prewashed with 40 vol of lysis buffer, pH 5.5, to remove endogenous folate (see above). After two 40-vol (18) . Fractions of2.75 ml were collected and counted for radioactivity. Recovery of the applied radioactivity in eluted fractions was > 85%. A duplicate sample was prepared as above except that during incubation with '25I-labeled PteGlu (histamine derivative) a 1,000-fold excess of unlabeled PteGlu was also added to the mixture to determine nonspecific '25I-labeled PteGlu (histamine derivative) binding.
Antigenic identity oferythrocyte FBPs. To determine if the solubilized erythrocyte FBPs were antigenically related to PFR (3), human PFR was purified to apparent homogeneity, (based on a single band on sodium dodecyl sulfate polyacrylamide gel electrophoresis), and antiserum to the purified protein was raised in rabbits as previously described (3). 1 ml of erythrocyte membranes were iodinated by the method of Markwell and Fox (19) using 400 gg Iodo-gen and 1 mCi 125I Na. After transfer of the quenched reaction mixture to a 15-ml Corex tube, the iodinated membranes were washed with 16 centrifuge-wash cycles with lysis buffer (30 vol per wash cycle). Incorporation of radioiodine into erythrocyte membranes ranged between 55 and 70% in five different experiments. The sample was solubilized with 2% Triton X-100 and 2% NP-40 and subjected to gel filtration chromatography, as described above. 10 gl of crude rabbit antiserum raised against the purified human PFR was added to 1.350 ml of each gel filtration fraction. The mixture was incubated on a shaking platform for 16 h at 4°C, following which 100 ul IgG Sorb was added to each tube. After incubation for 30 min at 4°C, the samples were centrifuged at 30,000 g for 60 min at 4°C. The supernatants were aspirated and the pellets were washed with 30 vol of lysis buffer for three cycles and counted for radioactivity. Simultaneous studies were performed on the second aliquot (1.350 ml) of each eluted fraction using 10 ll crude rabbit preimmune serum. Specific immunoprecipitation in each fraction was defined as the difference between total and nonspecific counts precipitated by immune anti-human PFR serum and by preimmune serum, respectively.
To determine if the moiety immunoprecipitated by anti-PFR serum was a folate binding protein, tubes containing 1 ml ofghosts that were pretreated to remove endogenous folate, as described above, were incubated with 35 pM '25I-labeled PteGlu (histamine derivative) in lysis buffer, pH 8, for 1 h at 37°C. After removal of unbound radioligand by four centrifuge-wash cycles, the pellets were counted for radioactivity. Each tube was subsequently solubilized with 1% deoxycholate (vol/vol) and 2% Triton X-100 (vol/vol) in a final volume of 3 ml at 40C for 18 h on a shaking platform. The samples were then centrifuged at 30,000 g for 30 min at 4°C to sediment insoluble material. The supernatants (2.9 ml) from each tube were subsequently incubated for 18 h at 4°C on a shaking platform with increasing concentrations of crude anti-human PFR serum diluted into a final volume of 100 M1 with crude rabbit preimmune serum. 1 ml of 20% polyethylene glycol (wt/vol) was then added to each tube and the mixture incubated for 10 min at 40C. After centrifugation at 30,000 g, for 1 h at 40C, the supernatants were aspirated and the pellets were counted for radioactivity. Simultaneous control studies were (20) . This process reduced the osmolarity to -100 mosM/liter. BSA (bovine serum albumin) powder (3 g) was added to the solution, which was further diluted to 291 ±1 mosM/liter by the addition of buffered saline glucose (BSG) (20) . The (1:20) and the decrease in absorbance was recorded over 5 min at 220C. The slope ofeach recording was calculated and activity was expressed in units per milligram of hemoglobin using an extinction coefficient of NADH = 6.22 (21) .
Red cell and leukocyte counts were determined using a Coulter counter (model M 430, Coulter Electronics, Hialeah, FL). Manual counting of reticulocytes were routinely determined among 10,000 cells after staining with brilliant cresyl blue (22) . Erythrocyte membranes from red cells separated on the basis of age were subsequently solubilized with 2% Triton X-100 and 1% deoxycholate, filtered through 0.2-,Mm Millex-GV filters and analyzed for protein content (23) . These samples were also subjected to the RIA to determine crossreacting material to the PFR as described above. Routinely, a dose response for each sample was assessed and the mean of three independent results (nanograms of cross-reacting material per milligam protein) was determined. A normal volunteer was subjected to phlebotomy of 300 ml whole blood per week for 2 mo while on a normal diet. This resulted in an increase in reticulocyte count to 2.6%. This individual's blood was used for study oferythrocyte FBPs after age-dependent separation of cells.
Results
Purity and stability of '25I-labeled PteGlu (histamine derivative). Preliminary studies using commercially available or synthesized [3H]PteGlu and 5-methyl-[3H]tetrahydrofolate were unable to identify specific folate binding to erythrocyte membranes due to the small number ofthese exposed folate binding moieties on these cells. Only with the availability of a folate derivative with -40-50-fold higher specific activity, was it possible to demonstrate P-FBPs on erythrocyte membranes.
The structure of "25I-labeled PteGlu (histamine derivative) is shown in Fig. 1 . The location of 125I is on the histamine ring, although its exact position has not been determined. Although this is an unnatural form of radiolabeled folate, its affinity for other FBPs from human placenta and milk was comparable to that obtained using [3HI or [14C]PteGlu in pilot studies. Studies were therefore undertaken to establish the purity of 125I-labeled PteGlu (histamine derivative) as well as its stability under the experimental conditions used in these studies. This was accomplished by conventional analytical procedures with HPLC and TLC. Fig. 2 shows the HPLC elution profile of commercially supplied 125I-labeled PteGlu (histamine derivative). There was a only single peak of radioactivity that corresponded to the maximum absorbance (A280) of '251-labeled PteGlu (histamine derivative), indicating its purity; when the peak fraction was reinjected into the column, the elution profile was identical to that of the commercially available '251I-la- mined. As shown in Table I , both unfractionated and HPLCpurified '25I-labeled PteGlu (histamine derivative) preparations bound erythrocyte membranes with similar high specificity and comparable extent. Finally, to verify that the radioactive species in unfractionated and HPLC-purified 1251_ labeled PteGlu (histamine derivative) that specifically bound to erythrocyte membranes was in fact '25I-labeled PteGlu (histamine derivative), membranes containing only bound radioligand were washed with lysis buffer, pH 5.5. This maneuver eluted > 90% of specifically bound radioactivity (see below); the eluates were subsequently analyzed by TLC. As shown in Figs. 3, C and D, only one species of radiolabeled material corresponding to HPLC-purified 125I-labeled PteGlu (histamine derivative) was observed. This suggested that the 1251-labeled PteGlu (histamine derivative) was unaltered following its binding to erythrocyte membranes. Although we have no data to directly prove that the radioactive label was not transferred in the course of these experiments (but remained in the imidazole ring), the experiments detailed above, as well as the fact that the iodination of the histamine derivative of folic acid with chloramine T involved covalent linkage, suggest that the radioactive label was authentic '25I-labeled PteGlu (histamine derivative). There was no significant loss of purity or erythrocyte membrane binding capacity even after 2 wk of storage of radioactive material at 4°C (not shown). Taken together, the data suggested that (a) commercially available unfractionated 125I-labeled PteGlu (histamine derivative) was of a high degree of purity as evidenced by a single species at A280, which corresponded to the major (> 99%) peak of radioactivity in eluted (Fig. 4 B) . Folate binding linearly increased as a function of erythrocyte membrane concentration (Fig. 4 C) , and was time and temperature dependent; ligand binding equilibrium was reached by 1 h at 37°C and 6 h at 4°C (Fig. 4 D) . The pH optimum for ligand binding was 7.5 ( Fig. 4 E, IgG Sorb, (100 Ml), and incubation for 30 mmn at 40C, the mixture was centrifuged to sediment IgG Sorb bound antibody complexed to iodinated proteins. The data in each eluted fraction is the difference between the precipitated radioactivity obtained using immune serum and preimmune serum. Both qualitatively and quantitatively similar results were obtained on five different studies on blood from the same individual.
antibody to the purified human placental folate receptor (3) . Although the '251-labeled PteGlu (histamine derivative)-bound FBPs eluting from the gel filtration column could be specifically immunoprecipitated with purified IgG from immune serum raised against the PFRt using either 5% polyethylene glycol or proteins A bearing S. aureus cells, the quantity of specifically precipitated FBPs was consistently lower in comparison to the total radioactivity in each FBP peak (data not shown). The reason for this was not clear but could be related to a higher proportion of blocking compared to immunoprecipitating antibodies in the polyclonal antiserum raised against the purified protein; these blocking antibodies could potentially displace bound "25I-labeled PteGlu (histamine derivative) from the FBPs. Therefore, after iodination of erythrocyte membranes followed by solubilization and Sephacryl S-200 gel filtration chromatography, the eluted fractions were probed with rabbit immune and preimmune serum. The results (Fig. 6  B) , identified two peaks of specifically immunoprecipitated material in the void volume and at Mr 160,000 corresponding to the elution position of 1251-labeled PteGlu (histamine derivative)-bound FBPs (Fig. 6 A) . Although solubilized iodinated membranes contained a moiety that was specifically immunoprecipitated by anti-PFR serum, findings consistent with earlier immunofluorescent studies (3), it was nevertheless necessary to determine if this species was a folate binding protein.
We found that 90% ofthe '251-labeled PteGlu (histamine derivative) previously bound to membranes was released into the supernatant after treatment of membranes with 2% Triton X-100 and 1% sodium deoxycholate. When the supernatant was reacted with increasing concentrations of anti-PFR anti- Tubes containing 5 mg of membranes that had bound '25I-labeled PteGlu (histamine derivative) were solubilized with lysis buffer containing 2% Triton X-100 and 1% deoxycholate over 18 h. After centrifugation at 30,000 g for 60 min at 4VC to remove insoluble material, the supernatants (2.9 ml) were incubated with increasing concentrations of crude rabbit anti-human placental folate receptor antiserum diluted in 100 ml preimmune serum for 18 h. I ml of 20% polyethylene glycol (wt/vol) was added to each tube and the mixture incubated for 10 min. After centrifugation at 30,000 g for 60 min the supernatants were aspirated and the pellets counted for radioactivity. Specific precipitation of '251-labeled PteGlu (histamine derivative)-bound solubilized FBP was determined from the difference between precipitated radioactivity in tubes containing various concentrations of antiserum and preimmune serum.
serum, there was a linear increase in specific precipitation of '25I-labeled PteGlu (histamine derivative)-bound protein (Fig.   7 ) which, at 100 Wd antiserum, constituted 38% of the total radioactivity. The inability to precipitate 100% of protein bound radioligand could be due to (a) competitive displacement of radioligand by unlabeled folates present in rabbit antiserum, or (b) partial homology of antigenic determinants between the erythrocyte FBP and PFR. The fact that the crude antiserum contained a higher concentration of folate (100 nM) compared with 37.5 nM folate present in preimmune serum could explain the former possibility. However, since preimmune serum precipitated < 5% of the total radioligand-bound protein at all levels compared to antiserum, the results nevertheless indicate that the erythrocyte FBP shared epitopes with the PFR. Taken together, the ligand binding data as well as the immunological studies suggest that the two erythrocyte membrane folate binding proteins were antigenically related to the FBPs from human milk, placenta, and KB cells, which share antigenic determinants that are recognized by the antiserum used in this study (3, 8, (18) (19) . The purified FBPs with apparent Mr of 160,000 on gel filtration in Triton X-100 from human milk (18) and KB cells (8, 24, 30) are hydrophobic detergent binding proteins, findings that are consistent with their association with membranes; it is therefore possible that the erythrocyte 160,000 Mr FBPs may have similar characteristics. Although the 2 200,000 Mr FBP may be unique to erythrocyte membranes, a more trivial explanation may be the incomplete solubilization from erythrocyte membranes by the non-ionic detergents used in this study. Further characterization ofdetergent binding and the Mr ofthese proteins by native and denaturing gel electrophoresis has been attempted; preliminary studies indicate, however, that further purification of these proteins is required due to the small amounts of these P-FBPs in erythrocytes (see below).
Identification of nonfunctional FBPs. Scatchard analysis from the folate binding isotherms indicated that in spite of removal of endogenous folate by "acid stripping" washes, there was less than one functional (in folate binding) molecule of FBP per erythrocyte. These results were not consistent with previous immunofluorescence studies on erythrocytes (3) that revealed both linear and beaded fluorescence in virtually every cell (albeit in varying degrees) when probed with anti-human PFR serum. A gross underestimation offunctional folate binding protein could be possible if a large amount of endogenous folate remained bound even after acid washing of membranes. However, when purified membranes (from 10 ml of erythrocytes) were assayed for the presence of endogenous folate by boiling for 30 min in the presence of reducing agents (8, 18) , no folate was released (detected) in the supernatant. To determine whether there was folate that remained bound to membrane FBPs even after the boiling process, two (indirect) tests were employed to investigate if FBPs were denatured and lost the ability to bind folate. In the first instance, membranes failed to bind '25I-labeled PteGlu (histamine derivative) after they were boiled; secondly, boiling membranes released 100% of bound '25I-labeled PteGlu (histamine derivative). Thus it was unlikely that endogenous folate remained bound to membrane FBPs to account for our inability to detect it in the assay for endogenous folate. We therefore hypothesized the presence of nonfunctional but immunoreactive folate binding proteins in these cells. '2SI-P;R, 10,000 cpm, was then added and incubation continued for an additional 18 h. IgG Sorb, 200 gl, was subsequently added and after 2 h at 4VC, the`2I-PFR-antibody complexes bound to IgG Sorb were sedimented and counted for radioactivity. Preimmune serum, 20 Ml, nonspecifically precipitated 28% of the total '12I-PFR, and this value, when subtracted from that precipitated with 0.2 Md immune serum, gave the 100% value (4,000 cpm) on the ordinate.
To test this possibility, a RIA was constructed that was based on the competitive binding of purified iodinated (Fig. 8  A) and unlabeled placental folate receptor by crude rabbit anti-human PFR serum; 1-antigen-antibody complexes were immunoprecipitated with protein A-bearing Staphylococcus aureus cells. The standard RIA assay curve (Fig. 8 B) had an upper limit ofsensitivity of 5 ng (0.1 pmol) and a lower limit of sensitivity of500 ng (10 pmol) PER. When solubilized erythrocyte membranes were tested in the RIA, they were found to contain 160±20 ng cross-reacting material/mg protein; this constituted 0.016% of the total solubilized erythrocyte membrane proteins. When the value of cross-reacting material per milligram of protein was converted to molar equivalents of FBPs and thence to molecules of protein per erythrocyte, (assuming that the true Mr of the FBP was -44,000 as has been shown with solubilized particulate FBPs from milk [18] and KB cells [30] ), there were 1,500±150 molecules/erythrocyte. It was therefore evident that there was a significant component of nonfunctional but immunoreactive FBP in erythrocytes. Fig. 9 , inset, the concentration of reticulocytes in the fractions declined rapidly from top to bottom and virtually no measurable reticulocytes were demonstrated in the bottom fraction (which contained aged red cells), whereas the maximum reticulocytes (12%) were concentrated in the top fraction. The PK activity was also maximum in the top fraction of the gradient and progressively declined; cells in the bottom fraction contained a 10-fold lower PK activity thus confirming the validity of the gradient in separating cells on the basis oftheir age. Also shown in Fig. 9 (3, 5-7, 12, 15, 24-29) . However, studies on folate uptake systems in several other intact mammalian cells including L-1210 cells (33) (34) (35) , PHA stimulated lymphocytes (36) , and human bone marrow cells (37) and human erythrocytes (10) suggest that transport was equally efficient and maximal for 5-methyltetrahydrofolate, 5-formyltetrahydrofolate and amethopterin, while that for PteGlu was poor.
With the exception of L1210 cells, where the affinity of the transport system for folates correlates with affinity for folates by surface membrane FBPs (34), competitive binding inhibition studies (similar to that reported with P-FBPs) using crude membranes or purified folate binding proteins from these cells (lymphocytes, bone marrow cells, and erythrocytes) have not been reported. Therefore, it is not known ifother unique folate transport proteins in these cells can bind and internalize various reduced folates more efficiently than PteGlu. Along these lines, we are currently investigating the basis for the apparent dichotomy between the high binding constants of erythrocyte FBPs for PteGlu and 5-methyltetrahydrofolate and the marked differences reported in the affinity of the transport system in intact human erythrocytes (10) . It should nevertheless be pointed out that in our recent studies with human KB cells, membrane-associated FBPs bound PteGlu and 5-methyltetrahydrofolate with high affinity, and intracellular transport of both folates were comparable and mediated by these FBPs (8, 24, 38 Recently, hemoglobin has been shown to possess a folate binding site (40) . Evidence to rule out the possibility that the observed binding of folate to erythrocyte membranes was through hemoglobin, which contaminated the membrane preparations are as follows: (a) the dissociation constant of erythrocyte folate binding moieties for folate were more consistent with that of a high affinity, low capacity system in the nanomolar range, while folate binding to hemoglobin was more consistent with a lower affinity, high capacity system (micromolar range); (b) there was apparently no difference in '25I-labeled PteGlu (histamine derivative) binding to "pink" membranes (which contained 100-fold more hemoglobin) compared to "white" membranes; (c) the specific immunoprecipitation of '251-labeled PteGlu These findings are similar to that observed with the insulin receptor on erythrocytes that decrease in direct proportion to the red cell aging process (31) . However, no direct studies of immunoreactive insulin receptor were reported to identify if there were similar findings as reported in our studies. The data presented for erythrocyte transferrin receptors is also different from our results. In that case (42) there is a proportionate and abrupt decrease in both transferrin binding and immunoreactive transferrin receptor when reticulocytes matured to erythrocytes. Since evaluation of transferrin receptor content was made on reticulocytes from patients with hemolytic anemias, (where the overall age of erythrocytes contaminating the reticulocytes would be younger), it is not known if the immunoreactive transferrin receptor is present in older erythrocytes as shown with FBPs. Nevertheless, immunofluorescent analysis of erythrocyte FBPs and transferrin receptors also showed major differences where FBPs were present in all red cells in varying degrees while transferrin receptors were only identified in reticulocytes. A discrepancy between the ligand binding studies and immunoreactive FBP has previously been observed with serum FBPs in normal individuals as well under various disease states (43) . The significance ofexcess immunoreactive nonfunctional FBPs in serum is unclear; in erythrocyte membranes it may be a reflection of FBP degradation during the aging process.
The first indirect evidence for a receptor role for plasma membrane-associated folate binding moieties in vivo were performed by Zamierowski and Wagner (44) (24) . The striking difference however, is the quantitatively higher content of these P-FBPs in KB cells (12) 
